About brolucizumab
Anti-VEGF eye medicine
Used for
- Treats wet age-related macular degeneration
- Treats diabetic macular edema
Usual adult dose
An eye specialist injects 6 mg into the affected eye; typically every 4 weeks for three doses, then every 8–12 weeks for wet age-related macular degeneration. Diabetic macular edema dosing is usually every 6 weeks for five doses, then every 8–12 weeks.
Common side effects
- Eye inflammation or pain
- Increased pressure inside the eye
- Floaters or blurred vision
- Cataract or retinal bleeding
Important warnings
- Rarely causes severe retinal blood-vessel inflammation or blockage and vision loss
- Seek urgent care for sudden vision changes, eye pain, redness, or light sensitivity
- Injections can cause eye infection or retinal detachment
- Avoid use during an active eye infection
Pregnancy
Human pregnancy information is limited. It may harm a fetus; use effective contraception during treatment and for at least one month after the last dose.
Breastfeeding
It is unknown whether brolucizumab passes into breast milk. Discuss treatment and breastfeeding timing with a healthcare professional.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.